Effect of flavonoids and CYP3A4 variants on midostaurin metabolism

被引:5
|
作者
Xu, Ren-ai [1 ,2 ]
Li, Qing-qing [2 ]
Gao, Nan-yong [2 ]
Wang, Jing [2 ]
Li, Xin-yue [2 ]
Ye, Feng [2 ]
Ni, Jin-huan [2 ]
Hu, Guo-xin [2 ,3 ]
Qian, Jian-chang [2 ,3 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325000, Peoples R China
[2] Wenzhou Med Univ, Inst Mol Toxicol & Pharmacol, Sch Pharmaceut Sci, Wenzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Peoples R China
基金
中国国家自然科学基金;
关键词
Flavonoids; Midostaurin; Genetic polymorphism; Myricetin; Interaction; ACUTE MYELOID-LEUKEMIA; GENETIC POLYMORPHISMS; IN-VIVO; PHARMACOKINETICS; ANTIBACTERIAL; INHIBITION; MYRICETIN; APIGENIN;
D O I
10.1016/j.fct.2023.113669
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The objective of this study was to determine the effect of flavonoids on midostaurin disposition considering co -administration and metabolic enzyme gene polymorphism. Enzymatic incubation assays were performed in vitro, while in vivo experiments were conducted in Sprague-Dawley rats. The analytes were determined via UPLC-MS/ MS. We found that myricetin was the most potent among the investigated 10 flavonoids in suppressing the metabolism of midostaurin, with an IC50 at a low mu M level. After co-administration of midostaurin and myricetin, the plasma concentration of midostaurin's primary metabolite CGP62221 was reduced corresponding to myr-icetin exposure. Furthermore, CYP3A4 homologous rat protein CYP3A2 was reduced significantly in the co -administration group. Thereafter, the kinetic parameters of 23 recombinant human CYP3A4 variants were determined using midostaurin. The relative intrinsic clearance varied from 269.63% in CYP3A4.29-8.95% in CYP3A4.17. In addition, the inhibitory potency of myricetin was substantially different for CYP3A4.29 and CYP3A4.17 compared with wild type, with IC50 values of 9.85 +/- 0.27 mu M and 90.99 +/- 16.13 mu M, respectively. Collectively, our data demonstrated that flavonoids, particularly myricetin, can inhibit the metabolism of mid-ostaurin. Additionally, CYP3A4 genetic polymorphism may contribute to stratification of midostaurin blood exposure.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
    Eiermann, B
    Engel, G
    Johansson, I
    Zanger, UM
    Bertilsson, L
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (05) : 439 - 446
  • [42] Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro
    Xie, Sai-li
    Zhu, Xiayan
    Gao, Nanyong
    Lin, Qianmeng
    Chen, Chaojie
    Yang, Yun-jun
    Cai, Jian-ping
    Hu, Guo-xin
    Xu, Ren-ai
    FOOD AND CHEMICAL TOXICOLOGY, 2023, 181
  • [43] Gut instincts: CYP3A4 and intestinal drug metabolism
    Thummel, Kenneth E.
    JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (11): : 3173 - 3176
  • [44] CYP3A4 drug metabolism considerations in pediatric pharmacotherapy
    Vander Schaaf, Marin
    Luth, Kyrle
    Townsend, Danyelle M.
    Chessman, Katherine H.
    Mills, Catherine M.
    Garner, Sandra S.
    Peterson, Yuri K.
    MEDICINAL CHEMISTRY RESEARCH, 2024, 33 (12) : 2221 - 2235
  • [45] In vitro metabolism of piperaquine is primarily mediated by CYP3A4
    Lee, Tina Ming-Na
    Huang, Liusheng
    Johnson, Marla K.
    Lizak, Patricia
    Kroetz, Deanna
    Aweeka, Francesca
    Parikh, Sunil
    XENOBIOTICA, 2012, 42 (11) : 1088 - 1095
  • [46] Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5
    Cook, CS
    Berry, LM
    Kim, DH
    Burton, EG
    Hribar, JD
    Zhang, LM
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) : 1344 - 1351
  • [47] Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4☆22 to Metabolism of Voriconazole"
    Walsh, Thomas J.
    Moriyama, Brad
    Penzak, Scott R.
    Klein, Teri E.
    Caudle, Kelly E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) : 187 - 187
  • [48] THE NEW CYP3A4 INTRON 6 POLYMORPHISM (CYP3A4*22) IS SIGNIFICANTLY ASSOCIATED WITH DECREASED TACROLIMUS METABOLISM.
    van Schaik, R. H.
    Elens, L.
    Bouamar, R.
    Hesselink, D. A.
    Haufroid, V.
    van Gelder, T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S107 - S107
  • [49] Identification and functional characterization of eight CYP3A4 protein variants
    Eiselt, R
    Domanski, TL
    Zibat, A
    Mueller, R
    Presecan-Siedel, E
    Hustert, E
    Zanger, UM
    Brockmoller, J
    Klenk, HP
    Meyer, UA
    Khan, KK
    He, YA
    Halpert, JR
    Wojnowski, L
    PHARMACOGENETICS, 2001, 11 (05): : 447 - 458
  • [50] Comparison of CYP3A4 and CYP3A5 in Drug Metabolism and Drug Interactions
    Li, Shuanmei
    Liu, Duan
    Zhu, Juanli
    Cui, Yan
    Zhou, Ruimin
    Chen, Chao
    DRUG METABOLISM REVIEWS, 2009, 41 : 31 - 32